Recombinant Baculovirus Associated with Bilosomes as an Oral Vaccine Candidate against HEV71 Infection in Mice

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Premanand, Balraj ^a   Prabakaran, Mookkan ^a   Kiener, Tanja K ^a   Kwang, Jimmy ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BACULOVIRUS VACCINE; BILOSOME; DRUG CARRIER; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY; PROTEIN VP1; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BACULOVIRUS; CONTROLLED STUDY; DRUG EFFICACY; ENTEROVIRUS 71; ENTEROVIRUS INFECTION; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; VIRUS ENVELOPE;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, VIRAL; BACULOVIRIDAE; ENTEROVIRUS A, HUMAN; FEMALE; HAND, FOOT AND MOUTH DISEASE; HUMANS; IMMUNITY, HUMORAL; IMMUNITY, MUCOSAL; IMMUNIZATION; LIPOSOMES; MICE; MICE, INBRED BALB C; VACCINES, SYNTHETIC; VIRAL STRUCTURAL PROTEINS; VIRAL VACCINES;

EID: 84873503828     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055536     Document Type: Article

References (52)

1. McMinn PC, (2002) An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 26: 91-107.
2. McMinn PC, (2012) Recent advances in the molecular epidemiology and control of human enterovirus 71 infection. Curr Opin Virol 2: 199-205.
3. Ang LW, Phoon MC, Wu Y, Cutter J, James L, et al. (2011) The changing seroepidemiology of enterovirus 71 infection among children and adolescents in Singapore. BMC Infect Dis 11: 270.
4. Fox G, Parry NR, Barnett PV, McGinn B, Rowlands DJ, et al. (1989) The Cell Attachment Site on Foot-and-Mouth Disease Virus Includes the Amino Acid Sequence RGD (Arginine-Glycine-Aspartic Acid). J. Gen. Virol 70: 625-637.
5. Pfaff E, Thiel HJ, Beck E, Strohmaier K, Schaller H, (1988) Analysis of neutralizing epitopes on foot-and-mouth disease virus. J. Virol 62: 2033-2040.
6. Rueckert RR (1990) Picornaviruses and their replication. In: Fields, B.N., Knipe, D.M. (Eds.). Virology Lippincott-Raven, New York 507.
7. Premanand B, Kiener TK, Meng T, Tan YR, Jia Q, et al. (2012) Induction of protective immune responses against EV71 in mice by baculovirus encoding a novel expression cassette for capsid protein VP1. Antiviral Res 95(3): 311-5.
8. Kolpe AB, (2012) Kiener TK, (2012) Grotenbreg GM, Kwang J, (2012) Display of enterovirus 71 VP1 on baculovirus as a type II transmembrane protein elicits protective B and T cell responses in immunized mice. Virus Res 168(1-2): 64-72.
9. Foo DG, Alonso S, Chow VT, Poh CL, (2007) Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect 9: 1299-1306.
10. Li X, Mao C, Ma S, Wang X, Sun Z, et al. (2009) Generation of neutralizing monoclonal antibodies against Enterovirus 71 using synthetic peptides. Biochem Biophys Res Commun 390: 1126-1128.
11. Tan CS, Cardosa MJ, (2007) High-titred neutralizing antibodies to human enterovirus preferentially bind to the N-terminal portion of the capsid proteinVP1. Arch. Virol 152: 1069-1073.
12. Wu CN, Lin YC, Fann C, Liao NS, Shih SR, et al. (2001) Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 20: 895-904.
13. Liu JN, Wang W, Duo JY, Hao Y, Ma CM, et al. (2010) Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine 28: 7444-51.
14. Tung WS, Bakar SA, Sekawi Z, Rosli R, (2007) DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther 5: 6.
15. Ogra PL, Faden H, Welliver RC, (2001) Vaccination strategies for mucosal immune responses. Clin. Microbiol. Rev 14: 430-445.
16. Chiu CH, Chu C, He CC, Lin TY, (2006) Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microbes Infect 8: 1671-1678.
17. Lotter H, Rüssmann H, Heesemann J, Tannich E, (2008) Attenuated recombinant Yersinia as live oral vaccine carrier to protect against amoebiasis. Int J Med Microbiol 298: 79-86.
18. Mann BJ, Burkholder BV, Lockhart LA, (1997) Protection in a gerbil model of amebiasis by oral immunization with Salmonella ex-pressing the galactose/N-acetyl D-galactosamine inhibitable lectin of Entamoeba histolytica. Vaccine 15: 659-63.
19. Cheng XJ, Tachibana H, (2001) Protection of hamsters from amebic liver abscess formation by immunization with the 150- and 170-kDa surface antigens of Entamoeba histolytica. Parasitol Res 87: 126-30.
20. Lotter H, Rüssmann H, Heesemann J, Tannich E, (2004) Oral vac-cina-tion with recombinant Yersinia enterocolitica expressing hybrid type III proteins protects gerbils from amebic liver ab-scess. Infect Immun 72: 7318-21.
21. Shoji I, Aizaki H, Tani H, Ishii K, Chiba T, et al. (1997) Efficient gene transfer into various mammalian cells, including non-hepatic cells, by bac-ulovirus vectors. J Gen Virol. 78: 2657-2664.
22. Prabakaran M, Madhan S, Prabhu N, Qiang J, Kwang J, (2010) Gastrointestinal delivery of baculovirus displaying influenza virus hemagglutinin protects mice against heterologous H5N1 infection. J Virol 84: 3201-3209.
23. Pauletti GM, Gangwar S, Knipp GT, Nerurkar MM, Okumu FW, et al. (1996) Structural requirements for intestinal absorption of peptide drugs. J Con Rel 41: 3-17.
24. Shalaby WSW, (1995) Development of oral vaccines to stimulate mucosal and systemic immunity:barriers and novel strategies. Clin Immunol Immunopath 74: 127-134.
25. Manna JFS, Ferro VA, Mullen AB, Tetley L, Mullen M, et al. (2004) Optimization of a lipid based oral delivery system containing A/Panama influenza hemagglutinin. Vaccine 22: 2425-2429.
26. Isaka M, Yasuda Y, Mizokami M, Kozuka S, Taniguchi T, et al. (2001) Mucosal immunization against hepatitis B virus by intranasal co-administration of recombinant cholera toxin B subunit as an adjuvant. Vaccine 19: 1460-1466.
27. Singh P, Prabakaran D, Jain S, Mishra V, Jaganathan KS, et al. (2004) Cholera toxin B subunit conjugate bile salt stabilized vesicles (bilosomes) for oral immunization. Int J Pharm 278: 379-390.
28. Mann JFS, Scales HE, Shakir E, Alexander JA, Carter KC, et al. (2006) Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity. Methods 38: 90-95.
29. Fry DW, White JC, Goldman ID, (1978) Rapid separation of low molecular weight solutes from liopsomes without dilution. Anal Biochem 90: 809-815.
30. LaBarre DD, Lowy RJ, (2001) Improvements in methods for calculating virus titer estimating TCID50 and plaque assays. J. Virol. Methods 96: 107-126.
31. Aarthi D, Ananda Rao K, Robinson R, Srinivasan VA, (2004) Validation of binary ethyleneimine (BEI) used as an inactivant for foot and mouth disease tissue culture vaccine. Biologicals 32: 153-156.
32. Rueda P, Fominaya J, Langeveld JPM, Bruschke C, Vela C, et al. (2000) Effect of different baculovirus inactivation procedures on the integrity and immunogenicity of porcine parvovirus-like particles. Vaccine 19: 726-734.
33. Meng T, Kolpe AB, Kiener TK, Vincent TK, Kwang J, (2011) Display of VP1 on the surface of Baculovirus and Its Immunogenicity against Heterologous Human enterovirus 71 Strains in Mice. PLoS One 6: e21757.
34. O'Reilly DR, Miller LK, Luckow VA (1992) Baculovirus expression vectors: a laboratory manual, p.60-61. W. H. Freeman and Company, New York, NY.
35. Conacher M, Alexander J, Brewer JM, (2001) Oral immunization with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes). Vaccine 19: 2965-2974.
36. Brewer JM, Roberts CW, Stimson WH, Alexander J, (1995) Accurate determination of adjuvant-associated protein or peptide by ninhydrin assay. Vaccine 13: 1441-4.
37. Syed MS, Kwang J, (2011) Oral vaccination of baculovirus-expressed VP28 displays enhanced protection against White Spot Syndrome Virus in Penaeus monodon. PLoS One 6(11): e26428.
38. Watarai S, Han M, Tana M, Kodama H, (1998) Antibody response in the intestinal tract of mice orally immunized with antigen associated with liposomes. J Vet Med Sci 60: 1047-1050.
39. Centers for Disease Control and Prevention (2004) Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 53: 1-40.
40. Ed C Lavelle, D T O'Hagan, (2006) Delivery systems and adjuvants for oral vaccines. Expert Opin Drug Deliv 3: 747-762.
41. Kost TA, Condreay JP, (2002) Recombinant baculoviruses as mammalian cell gene-delivery vectors. Trends Biotechnol 20: 173-179.
42. Tani,H, Limn CK, Yap CC, Onishi M, Nozaki M, et al. (2003) In vitro and in vivo gene delivery by recombinant baculoviruses. J Virol 77: 9799-9808.
43. Kinnunen K, Kalesnykas G, Mahonen AJ, Laidinen S, Holma L, et al. (2009) Baculovirus is an efficient vector for the transduction of the eye: comparison of baculovirusand adenovirus-mediated intravitreal vascular endothelial growth factor D gene transfer in the rabbit eye. J Gene Med 11: 382-389.
44. Moldoveanu Z, Novak M, Juanh W-Q, Gilley RM, Staas JK, et al. (1993) Oral immunization with influenza virus in biodegradable microspheres. J Infect Dis 167: 84-90.
45. Allaoui-Attarki K, Fattal E, Pecquet S, Trolle S, Chachaty E, et al. (1998) Mucosal immunogenicity elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly (D,L-lactide-co-glycolide) microspheres. Vaccine 16: 685-91.
46. Chen SC, Jones DH, Fynan EF, Farrar GH, Clegg JCS, et al. (1998) Protective immunity by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. J Virol 72: 5757-61.
47. Ghazi HO, Potter CW, Smith TL, Jennings R, (1995) Comparative antibody responses and protection in mice immunized by oral or parenteral routes with influenza virus subunit antigens in aqeous form or incorporated into ISCOMs. J Med Microbiol 42: 53-61.
48. Maloy KJ, Donachie AM, Mowat AM, (1995) Induction of Th1 and Th2 CD4+ T cell responses by oral or parenteral immunization with ISCOMs. Eur J Immunol 25: 2835-41.
49. Mann JF, Shakir E, Carter KC, Mullen AB, Alexander J, et al. (2009) Lipid vesicle size of an oral influenza delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection. Vaccine 27: 3643-3649.
50. Tjia ST, zu Altenschildesche GM, Doerfler W, (1983) Autographa californica nuclear polyhedrosis virus (AcNPV) DNA does not persist in mass culture of mammalian cells.Virology. 125: 107-117.
51. Strauss R, Huser A, Ni S, Tuve S, Kiviat N, et al. (2007) Baculovirus-based vaccination vectors allow for efficient induction of immune responses against Plasmodium circumsporozoite protein Mol Ther. 15: 193-202.
52. Hu YC, Tsai CT, Chung YC, Ku JT, Hsu JT, (2003) Generation of chimeric baculovirus with histidine-tags displayed on the envelope and its purification using immobilized metal affinity chromatography. Enzyme Microb Technol 33: 445-452.